Catalent (NYSE:CTLT) is scheduled to be announcing its earnings results before the market opens on Monday, February 5th.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.01. The business had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The firm’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.16 EPS. On average, analysts expect Catalent to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Catalent (NYSE CTLT) opened at $47.36 on Monday. The stock has a market capitalization of $6,290.00, a P/E ratio of 55.07, a P/E/G ratio of 2.97 and a beta of 1.41. Catalent has a 12-month low of $25.89 and a 12-month high of $47.46. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49.
In related news, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction dated Tuesday, November 21st. The stock was purchased at an average cost of $39.22 per share, for a total transaction of $294,150.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, insider John R. Chiminski sold 181,458 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by insiders.
WARNING: “Catalent (CTLT) Scheduled to Post Quarterly Earnings on Monday” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/29/catalent-ctlt-scheduled-to-post-quarterly-earnings-on-monday.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.